Forum: BioPharma » Bioalliance Pharma richting € 8 in 2014 ? Heden; € 4,25. » Pagina: 23

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Vanaf 13,95 per maand leest u dagelijks onze professionele aandelenanalyses en kooptips.

Krijg toegang tot vele voordelen

Onbeperkt toegang tot onze Premium-content
Ons magazine IEX Expert (digitaal of papier)
Toegang tot onze 3 modelportefeuilles

Profiteer van de IEX producten

3 Modelportefeuilles
Dividendkalender
Aandelenselector

[verwijderd] 11 februari 2015 08:16

[verwijderd]

Lid sinds: 01 jan 0001

Laatste bezoek: 01 jan 0001
Aanbevelingen

Ontvangen: 0

Gegeven: 0
Aantal posts: 0

Onxeo strengthens its executive management team

10 FEB, 2015
Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO), an innovative company specialised in orphan oncology treatments, has strengthened its management team with three new senior appointments.

- Elisabeth Carstensen appointed Director of Alliance Management
- Graham Dixon appointed CSO/Head of R&D
- Audrey Legentil-Duméry appointed Director of Human Resources

Judith Greciet, CEO of Onxeo, declared: “Significantly strengthening our executive management team goes hand in hand with the implementation of our strategic growth plan. Partnerships, R&D and HR are all crucial to accelerating our development and succeeding in our ambition to become a global leader in orphan oncology. Stemming from varied cultural backgrounds and perfectly accustomed to operating in the biotech universe, I am convinced that Elisabeth, Graham and Audrey will greatly contribute to Onxeo’s future development.”

Elisabeth Carstensen, Director of Alliance Management

Elisabeth will head a newly created department responsible for coordinating and optimising Onxeo’s relationships with commercial as well as international development partners, significant sources of revenues for the company. Elisabeth Carstensen holds a PhD in organic chemistry and a Master’s degree in chemical engineering from the Technical University of Denmark. Initially responsible for the pharmaceutical development of Belinostat, Elisabeth was lately Director of Business Development and Partnership Management with Topotarget. Elisabeth has also been appointed Director of Onxeo’s Danish operation, ensuring the link between the group’s two entities.

Graham Dixon, CSO/ Head R&D

Heading the R&D department, Graham Dixon, will be responsible with his teams for leading project development up through commercialisation, strengthening portfolio projects and fostering collaboration with academic experts on promising programmes.

Graham Dixon has a twenty year track record in research and development in pharmaceutical industry, particularly oncology, having held senior management positions within big pharma and biotech. For nearly ten years, Graham worked as Director of R&D with the European biotech Galapagos, accompanying its growth and international development.

Graham Dixon holds a PhD in Biochemistry from the University of Swansea, Wales and an honors degree in Biology from the Universtiy of Bradford. He has numerous patents and scientific publications.

Audrey Legentil-Duméry, Director of Human Resources

A human resources department, headed by Audrey Legentil-Duméry, has been created to support Onxeo’s rapid growth and will support international development and talent management, notably in the integration of the French and Danish teams. Previously, Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris-based agency, managing HR on behalf of diverse companies, notably accompanying SME’s through periods of growth and transition. Audrey successfully conducted several missions in the pharma and biotech sectors. Audrey holds a degree in Management and Intercultural Communication from CELSA (Sorbonne, Paris).

Pierre Attali, MD, MSc, General Deputy Manager in charge of Strategy and Medical Affairs, is leaving the company to focus on other projects and may continue to collaborate with Onxeo as an advisor.

www.onxeo.com/en/onxeo-strengthens-ex...

Direct naar Forum

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

AEX	887,44	+0,99%
EUR/USD	1,0766	+0,38%
FTSE 100	8.213,49	+0,51%
Germany40^	18.020,60	+0,69%
Gold spot	2.301,12	-0,11%
NY-Nasdaq Composite	15.840,96	+1,51%

VIVORY...	+0,05 +7,18% 0.051 7.1831
Flow T...	+0,95 +4,87% 0.95 4.8743
BESI	+4,95 +4,11% 4.95 4.1113
Brunel	+0,40 +3,91% 0.4 3.9063
UMG	+1,01 +3,62% 1.01 3.6188

HEIJMA...	-0,90 -5,17% -0.9 -5.1665
Aperam	-1,24 -4,56% -1.24 -4.5555
AMG Cr...	-0,74 -3,16% -0.74 -3.1597
Kendrion	-0,36 -2,75% -0.36 -2.7523
CM.COM	-0,15 -2,24% -0.15 -2.2388

Beurscodes, betekenis en hulp bij zoeken

Europa

Noord-Amerika

Kunt u een instrument niet vinden?

Waar vind ik die ISIN code?

Inloggen

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Krijg toegang tot vele voordelen

Profiteer van de IEX producten

Nederland

Europa

Amerika

BioPharma« Terug naar discussie overzicht

Bioalliance Pharma richting € 8 in 2014 ? Heden; € 4,25.

[verwijderd]

Aanbevelingen

Aantal posts: 0

[verwijderd]

Aanbevelingen

Aantal posts: 0

Meedoen aan de discussie?

Direct naar Forum

Indices

Stijgers

Dalers

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Nederlandse MKB Participatiemaatschappij

Pearl Capital: beleggen met zekerheid

Hét Warren Buffett-pakket al aangevraagd?

MeManaged vermogensbeheer

Bitvavo

Meld u aan voor de dagelijkse Beursupdate

Verzoek